Ozempic and Wegovy should be covered by Medicare as weight loss treatments: KFF poll
About half of adults with insurance said they had trouble paying for weight loss drugs, according to a new survey, which are currently not covered by Medicare.
GLP-1 drugs such as Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro—which are used to treat diabetes and heart disease—are having a moment in the sun as treatments for weight loss. While Wegovy has been cleared by the Food and Drug Administration (FDA) to treat weight loss and heart disease, Ozempic (which is the same drug as Wegovy just in a lower dose) and Mounjaro are only approved to treat diabetes.